Skip to main content
Autobound logo
Merck10-Q: Compliance burden

Merck faces multiple critical FDA PDUFA deadlines in mid-to-late 2026

Read at SEC EDGAR

What happened

The company has several FDA decision deadlines (PDUFA dates) for key drugs in 2026, including for Welireg (June 19, Oct 4), Keytruda (Aug 17), and Winrevair (Sept 21). This creates immense pressure on regulatory affairs and data management teams to ensure flawless execution to secure approvals.

Source

SEC EDGARMay 4, 2026

Quarterly report (Form 10-Q)

Merck 10-Q

Filing excerpt

Keytruda and Keytruda Qlex are under priority review by the FDA... The FDA set a PDUFA date of August 17, 2026.

sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
03/31
Filed
May 4, 2026

More from Merck

Company page →

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
310158
Accession number
0001628280-26-029802
Timeframe
Current year
Filing year
2026
Fiscal year
0
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Competitors

  • Pfizer
  • Astellas
  • Gilead Sciences Inc.

Regions named

  • U.S.
  • EU
  • Japan

Extraction

Confidence
High
Relevance
80%
Sentiment
Neutral
Detected
May 5, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/1429ba3e-48ad-4747-a123-77e9b1b7474a returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "1429ba3e-48ad-4747-a123-77e9b1b7474a",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-05-05T08:48:22.077+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "The company has several FDA decision deadlines (PDUFA dates) for key drugs in 2026, including for Welireg (June 19, Oct 4), Keytruda (Aug 17), and Winrevair (Sept 21). This creates immense pressure on regulatory affairs and data management teams to ensure flawless execution to secure approvals.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Merck faces multiple critical FDA PDUFA deadlines in mid-to-late 2026",
    "excerpts": "Keytruda and Keytruda Qlex are under priority review by the FDA... The FDA set a PDUFA date of August 17, 2026.",
    "relevance": 0.8,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm",
    "filing_date": "2026-05-04",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S.",
      "EU",
      "Japan"
    ],
    "competitors_mentioned": [
      "Pfizer",
      "Astellas",
      "Gilead Sciences Inc."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.